RMANJ and Valencian Infertility Institute Announce Creation of Largest Global Fertility Network
 
NJ Health News on mybergen.com
 

The management division of Reproductive Medicine Associates of New Jersey (RMANJ) and The Valencian Infertility Institute (IVI) announced they are combining their businesses to create a new company called IVI-RMA Global.

IVI-RMA Global, will be the largest and one of the most successful global fertility networks providing assisted reproduction and related services. RMANJ Management, its affiliated practice, RMANJ, and IVI will all continue to operate under their current names in their respective countries.

Once the transaction is complete, IVI-RMA Global and its affiliated practices will have nearly 2,400 employees across 70 locations around the world, maintaining a team of over 200 physicians, and over 300 scientists and researchers. IVI-RMA Global and its board of directors, which will be comprised of the founding partners of IVI and RMANJ, will oversee several different international business units, including the newly created IVI America. One of IVI America’s core goals will be to expand the combined company’s footprint in the United States and Canada.

“As one unified global entity, our commitment to offering evidence-based fertility solutions that offer the greatest chance of success in the shortest time necessary knows no boundaries – geographic or otherwise. Last year patients came to RMANJ from over 30 US states and 40 countries. Now together with IVI, we’re better positioned to enter new markets and help bring new hope to new patients,” added Dr. Richard T. Scott, Jr., a founding partner and laboratory director of RMANJ.

Founded in 1999, RMANJ is one of the largest and most successful IVF programs in the US and flagship for the RMA network of practices. RMANJ has grown nearly 70% in new patients over the last five years. This far exceeds US growth rate trends thanks to scientific innovations such as Comprehensive Chromosome Screening (CCS), a commitment to Frozen Embryo Transfer (FET) and an overall evidence-based clinical paradigm that has generated IVF success rates well above the US average for more than a decade.

“I have known Dr. Scott for many years, and we admire and respect each other. I have always pursued the goal of introducing our company to the United States, and today I am pleased to announce that we have made it. The key to achieve this step was RMANJ. We share much of the same medical-scientific and business values and interests. This alliance will allow us to take full advantage of the expertise, experience and distinguishing elements of both companies for the benefit of our patients and employees,” offered Dr. Antonio Pellicer, President, IVI.

Dr. José Remohí declared that “after the transaction with RMANJ Management, we will consolidate our position as the largest fertility network in the world. Being in the United States is a dream come true and RMA of New Jersey proved to be the best companion. They are commercial and scientific leaders in reproductive medicine in the United States. This union will allow us to enhance our field of investigation, the fundamental pillar of IVI since its inception which has enabled us to achieve high rates of success – a fact that our patients value when choosing our services.”

Founded in 1990, under the leadership of Dr. Antonio Pellicer and Dr. José Remohí, IVI grew into a scientific and commercial leader in the field of reproductive endocrinology with numerous awards and innovations to its name. At the end 2016, the practice had 60 locations in 11 countries worldwide, and treated over 60,000 patients.

RMANJ is represented by McDermott Will & Emery LLP (United States), Olleros Abogados (Spain), and Dresner Partners (United States). IVI is represented by Garrigues Abogados (Spain) and Arcano Group (Spain) in connection with the transaction.